Advanced Biotherapy, Inc.

Agreement signed for humanized antibody to interferon-gamma

Published in Pharma Law Weekly, June 1st, 2004

Advanced Biotherapy, Inc., (ADVB) and Innogenetics NV (INNX) announced the signing of a cross-licensing agreement combining Innogenetics' patented humanized antibody to interferon-gamma (known as INNO 202) and Advanced Biotherapy's intellectual property in the field of various immune diseases involving interferon-gamma.

By granting each other access to their respective intellectual property, the agreement provides a broader, joint position to attract interested third parties when negotiating mutually relevant development and commercial license agreements. The first clinical indication targeted in this arrangement is rheumatoid arthritis, but the agreement provides both...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2004-06-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry